One strategy to circumvent NK cell suppression by the adenosinergic pathway would be to target A3R and/or A2AR because data show that A3R agonists and A2AR antagonists activate NK cells and further improve their anti-tumor effects in a melanoma mouse model in vivo [122,123]. This evidence concerns the gene ADORA2A and melanoma.